To test if PBMC-delivered mLIGHT-armed MYXV conferred increased therapeutic efficacy in the K7M2-luc lung metastatic model, vMyx-mLIGHT/PBMC and the combination vMyx-mLIGHT/PBMC + anti-PD-1 was tested in a more advanced later-stage model of lung disease. This evidence concerns the gene PDCD1 and lung disorder.